James Cordon has spoken out about using Ozempic and shared with the world his findings. While speaking with guest Richard ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

“A prescriber, for instance, could not write Wegovy ... drug,” Noom CEO Geoff Cook said of the prices for his company’s ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...

Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.